Literature DB >> 34240320

Cerebral mucormycosis: neuroimaging findings and histopathological correlation.

François Lersy1, Julie Royer-Leblond2, Benoit Lhermitte3, Agathe Chammas1, Francis Schneider4, Yves Hansmann5, Nicolas Lefebvre5, Julie Denis6, Marcela Sabou6,7, François Lafitte8, François Cotton9,10, Marie-Paule Boncoeur-Martel11,12,13,14, Thomas Tourdias15,16, Jean-Pierre Pruvo17,18, Jean-Philippe Cottier19, Raoul Herbrecht20, Stéphane Kremer21,22.   

Abstract

INTRODUCTION: Mucormycosis are infections caused by molds of the order Mucorales. These opportunistic infections are rare, difficult to diagnose, and have a poor prognosis. We aimed to describe common radiographic patterns that may help to diagnose cerebral mucormycosis and search for histopathological correlations with imaging data.
METHODS: We studied the radiological findings (CT and MRI) of 18 patients with cerebral mucormycosis and four patients' histopathological findings.
RESULTS: All patients were immunocompromised and/or diabetic. The type of lesions depended on the infection's dissemination pathway. Hematogenous dissemination lesions were most frequently abscesses (59 lesions), cortical, cortical-subcortical, or in the basal ganglia, with a halo aspect on DWI for lesions larger than 1.6 cm. Only seven lesions were enhanced after contrast injection, with different presentations depending on patients' immune status. Ischemia and hemorrhagic areas were also seen. Vascular lesions were represented by stenosis and thrombosis. Direct posterior extension lesions were bi-fronto basal hypodensities on CT and restricted diffusion without enhancement on MRI. A particular extension, perineural spread, was seen along the trigeminal nerve. Histopathological analysis found endovascular lesions with destruction of vessel walls by Mucorales, microbleeds around vessels, as well as acute and chronic inflammation.
CONCLUSIONS: MRI is the critical exam for cerebral mucormycosis. Weak ring enhancement and reduced halo diffusion suggest the diagnosis of fungal infections. Involvement of the frontal lobes should raise suspicion of mucormycosis (along with aspergillosis). The perineural spread can be considered a more specific extension pathway of mucormycosis.
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cerebral mucormycosis; Fungal; Invasive fungal infections; MRI; Mucormycosis

Mesh:

Year:  2021        PMID: 34240320     DOI: 10.1007/s00415-021-10701-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis.

Authors:  F Lanternier; S Poiree; C Elie; D Garcia-Hermoso; P Bakouboula; K Sitbon; R Herbrecht; M Wolff; P Ribaud; O Lortholary
Journal:  J Antimicrob Chemother       Date:  2015-08-27       Impact factor: 5.790

2.  Rhino-orbito-cerebral mucormycosis. Management strategies to avoid or limit intracraneal affection and improve survival.

Authors:  Olga Plowes Hernández; Héctor M Prado Calleros; Galo Santiago Soberón Marmissolle Daguerre; Andrés Sadek González
Journal:  Acta Otorrinolaringol Esp       Date:  2015-06-03

3.  Perineural spread of rhinocerebral mucormycosis.

Authors:  F M McLean; L E Ginsberg; C A Stanton
Journal:  AJNR Am J Neuroradiol       Date:  1996-01       Impact factor: 3.825

Review 4.  Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives.

Authors:  Kyung J Kwon-Chung
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

5.  Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007.

Authors:  A Skiada; L Pagano; A Groll; S Zimmerli; B Dupont; K Lagrou; C Lass-Florl; E Bouza; N Klimko; P Gaustad; M Richardson; P Hamal; M Akova; J F Meis; J-L Rodriguez-Tudela; E Roilides; A Mitrousia-Ziouva; G Petrikkos
Journal:  Clin Microbiol Infect       Date:  2011-07-01       Impact factor: 8.067

6.  Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

Authors:  Francisco M Marty; Luis Ostrosky-Zeichner; Oliver A Cornely; Kathleen M Mullane; John R Perfect; George R Thompson; George J Alangaden; Janice M Brown; David N Fredricks; Werner J Heinz; Raoul Herbrecht; Nikolai Klimko; Galina Klyasova; Johan A Maertens; Sameer R Melinkeri; Ilana Oren; Peter G Pappas; Zdeněk Ráčil; Galia Rahav; Rodrigo Santos; Stefan Schwartz; J Janne Vehreschild; Jo-Anne H Young; Ploenchan Chetchotisakd; Sutep Jaruratanasirikul; Souha S Kanj; Marc Engelhardt; Achim Kaufhold; Masanori Ito; Misun Lee; Carolyn Sasse; Rochelle M Maher; Bernhardt Zeiher; Maria J G T Vehreschild
Journal:  Lancet Infect Dis       Date:  2016-03-09       Impact factor: 25.071

Review 7.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

8.  Forty-one recent cases of invasive zygomycosis from a global clinical registry.

Authors:  M J G T Rüping; W J Heinz; A J Kindo; V Rickerts; C Lass-Flörl; C Beisel; R Herbrecht; Y Roth; G Silling; A J Ullmann; K Borchert; G Egerer; J Maertens; G Maschmeyer; A Simon; M Wattad; G Fischer; J J Vehreschild; O A Cornely
Journal:  J Antimicrob Chemother       Date:  2009-12-11       Impact factor: 5.790

9.  Rhinocerebral mucormycosis: changing patterns of disease.

Authors:  E S Nussbaum; W A Hall
Journal:  Surg Neurol       Date:  1994-02

10.  Imaging findings of rhinocerebral mucormycosis.

Authors:  Diego A Herrera; Arthur B Dublin; Eleanor L Ormsby; Shervin Aminpour; Lydia P Howell
Journal:  Skull Base       Date:  2009-03
View more
  1 in total

1.  Successful treatment of rhino-cerebral mucormycosis with dual antifungal therapy and minimal surgical debridement.

Authors:  Lauren Bougioukas; Cindy D Noyes; Katherine Peterson; Lindsay M Smith; Andrew J Hale
Journal:  IDCases       Date:  2022-09-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.